logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 17 of 17 Items
Showing 1 - 17 of 17 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia

Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A,  et al.
2025-04-09 • Antimicrobial Agents and Chemotherapy
2025-04-09 • Antimicrobial Agents and Chemotherapy

Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...

Journal Article
|
Letter

Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin

Rupasinghe P, Ashraf A, Barreda N, Parveen S, Zubair M,  et al.
2024-05-02 • Antimicrobial Agents and Chemotherapy
2024-05-02 • Antimicrobial Agents and Chemotherapy
Journal Article
|
Protocol

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Journal Article
|
Research

Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study

Huerga H, Bastard M, Lubega AV, Akinyi M, Antabak NT,  et al.
2023-01-01 • Lancet Global Health
2023-01-01 • Lancet Global Health
BACKGROUND
Development of rapid biomarker-based tests that can diagnose tuberculosis using non-sputum samples is a priority for tuberculosis control. We aimed to compare the diagnost...
Journal Article
|
Research

Evaluation of OMNIgene® SPUTUM and ethanol reagent for preservation of sputum prior to Xpert and culture testing in Uganda

Ardizzoni E, Orikiriza P, Ssuuna C, Nyehangane D, Gumsboga M,  et al.
2019-10-16 • Journal of Clinical Microbiology
2019-10-16 • Journal of Clinical Microbiology
Background: Xpert MTB/RIF (Xpert) and culture are the most reliable methods for tuberculosis diagnosis but are still poorly accessible in many low resource countries. We aimed to assess ...
Journal Article
|
Research

Implementing the Xpert MTB/RIF diagnostic test for tuberculosis and rifampicin resistance: outcomes and lessons learned in 18 countries

Ardizzoni E, Fajardo E, Saranchuk P, Casenghi M, Page AL,  et al.
2015-12-15 • PLOS One
2015-12-15 • PLOS One
BACKGROUND
The Xpert® MTB/RIF (Xpert) is an automated molecular test for simultaneous detection of tuberculosis (TB) and rifampicin resistance, recommended by the World Health Organi...
Journal Article
|
Research

MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era

Beckert P, Sanchez-Padilla E, Merker M, Dreyer V, Kohl TA,  et al.
2020-11-25 • Genome Medicine
2020-11-25 • Genome Medicine
Background
Multidrug-resistant (MDR) Mycobacterium tuberculosis complex strains not detected by commercial molecular drug susceptibility testing (mDST) assays due to the RpoB I491F ...
Journal Article
|
Research

Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda

Checchi F, Piola P, Kosack CS, Ardizzoni E, Klarkowski DB,  et al.
2004-04-01 • Tropical Medicine and International Health
2004-04-01 • Tropical Medicine and International Health
We report below an in vivo antimalarial efficacy study conducted in 2002 in Bundi Bugyo, a district of western Uganda housing a large displaced population. We tested sulfadoxine-pyrimeth...
Journal Article
|
Research

Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children

Orikiriza P, Smith JS, Ssekyanzi B, Nyehangane D, Mugisha IT,  et al.
2021-06-17 • European Respiratory Journal
2021-06-17 • European Respiratory Journal
BACKGROUND
Non-sputum-based diagnostic approaches are crucial in children at high risk of disseminated tuberculosis (TB) who cannot expectorate sputum. We evaluated the diagnostic ac...
Journal Article
|
Protocol

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E,  et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...
Journal Article
|
Research

Routine use of Xpert MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis

Page AL, Ardizzoni E, Lassovsky M, Kirubi B, Bichkova D,  et al.
2015-06-30 • International Journal of Tuberculosis and Lung Disease
2015-06-30 • International Journal of Tuberculosis and Lung Disease
SETTING
Despite the widespread introduction of Xpert® MTB/RIF in developing countries, reports of its use and value in routine conditions remain limited.

OBJECTIVE
To de...
Journal Article
|
Research

The thin-layer agar method for direct phenotypic detection of multi- and extensively drug-resistant tuberculosis

Ardizzoni E, Mulders W, Kotrikadze T, Goginashvili L, Pangtey H,  et al.
2015-12-02 • International Journal of Tuberculosis and Lung Disease
2015-12-02 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Molecular techniques rapidly detect resistance to rifampicin (RMP) and isoniazid (INH), but do not eliminate the need for culture-based drug susceptibility testing (DST) a...
Journal Article
|
Research

Nontuberculous mycobacteria infections at a provincial reference hospital, Cambodia

Bonnet MMB, Chamroeun San K, Pho Y, Sok C, Dousset JP,  et al.
2017-07-01 • Emerging Infectious Diseases
2017-07-01 • Emerging Infectious Diseases
Prevalence of nontuberculous mycobacteria (NTM) disease is poorly documented in countries with high prevalence of tuberculosis (TB). We describe prevalence, risk factors, and TB program ...
Journal Article
|
Research

Incremental yield of including Determine-TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV-positive patients in Kenya

Huerga H, Ferlazzo G, Bevilacqua P, Kirubi B, Ardizzoni E,  et al.
2017-01-26 • PLOS One
2017-01-26 • PLOS One
BACKGROUND
Determine-TB LAM assay is a urine point-of-care test useful for TB diagnosis in HIV-positive patients. We assessed the incremental diagnostic yield of adding LAM to algori...
Journal Article
|
Research

Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions

Sanchez-Padilla E, Ardizzoni E, Sauvageot D, Ahoua L, Martin AIC,  et al.
2013-08-01 • International Journal of Tuberculosis and Lung Disease
2013-08-01 • International Journal of Tuberculosis and Lung Disease
Despite major progress in the surveillance of drug-resistant tuberculosis (TB), data are lacking for many low-resource countries. World Health Organization estimates of multidrug-resista...
Journal Article
|
Research

Performance of the 2007 WHO Algorithm to diagnose Smear-negative Pulmonary Tuberculosis in a HIV prevalent setting

Huerga H, Varaine FFV, Okwaro E, Bastard M, Ardizzoni E,  et al.
2012-12-19 • PLOS One
2012-12-19 • PLOS One
BACKGROUND
The 2007 WHO algorithm for diagnosis of smear-negative pulmonary tuberculosis (PTB) including Mycobacterium tuberculosis (MTB) culture was evaluated in a HIV prevalent are...
Journal Article
|
Research

Mortality in the first six months among HIV-positive and HIV-negative patients empirically treated for tuberculosis

Huerga H, Ferlazzo G, Wanjala S, Bastard M, Bevilacqua P,  et al.
2019-02-11 • BMC Infectious Diseases
2019-02-11 • BMC Infectious Diseases
Empirical treatment of tuberculosis (TB) may be necessary in patients with negative or no Xpert MTB/RIF results. In a context with access to Xpert, we assessed mortality in the 6 months ...